Latest From Tricida Inc.
US FDA advisory committee meetings held in close proximity to user fee goal dates are approved at a similar rate to all products reviewed by the advisory panels, according to a Pink Sheet analysis of drug and biologic advisory committees since 2015.
Almost 50 novel agents are already under review at FDA for potential 2020 approval. Candidates are notably diverse, with concentrations in established strongholds (oncology, neuroscience), popular programs (breakthrough), and powerhouse sponsors (keep an eye on Bristol-Myers Squibb right out of the gate).
Keeping Track: Ofev Snags SSc-ILD Indication, Accelerated Approval Reviews For Veverimer And Voxelotor, J&J Gets Its First Vaccine BTD
The latest drug development news and highlights from our US FDA Performance Tracker.
Public Company Edition: NGM went public a week after Genfit, but endured a rockier start, trading below its IPO price. Also, Blueprint, Tricida and Sangamo launch large offerings after positive clinical and regulatory updates.
- Therapeutic Areas
- Renal System
- Trilypsa Inc.
- North America
- Parent & Subsidiaries
- Tricida Inc.
- Senior Management
Gerrit Klaerner, PhD, Pres. & CEO
Geoffrey Parker, SVP, CFO
Claire Lockey, SVP, Chief Dev. Officer
Susannah Cantrell, PhD, SVP, Chief Commercial Officer
- Contact Info
Phone: (415) 429-7800
7000 Shoreline Ct.
South San Francisco, CA 94080